BackMilestone Pharmaceuticals Overview

Milestone Pharmaceuticals Other Current Liabilities

Milestone Pharmaceuticals's other current liabilities is $15M.

Get informed when a big investor buys or sells

+ Follow
Other Current Liabilities
$14.54M
↑ 44.80% YoYΔ $4.50M vs prior year quarter

Peer trimmed avg / median

Loading

Milestone Pharmaceuticals Other Current Liabilities History

Loading

Milestone Pharmaceuticals vs. peers: Other Current Liabilities Comparison

Loading

Milestone Pharmaceuticals Other Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Milestone Pharmaceuticals (MIST) FAQ

Milestone Pharmaceuticals's other current liabilities stands at $15M as of September 2026. That compares with $10M in the prior-year period — up 44.8% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Milestone Pharmaceuticals reported $15M in other current liabilities versus $10M a year earlier — a 44.8% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $10M in the prior-year period — up 44.8% year over year. Sustained growth in other current liabilities can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Milestone Pharmaceuticals's other current liabilities evolved across reporting periods, while the comparison chart places MIST next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, other current liabilities is commonly used to spot outliers. Milestone Pharmaceuticals's reading of $15M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.